Drug giant Pfizer is informing hospitals that dozens of its products could face “continued or new supply disruptions in the near-term” after an EF-3 tornado last week severely damaged its plant in ...

Pfizer Inc ($PFE) announced an update on their ongoing clinical study. Pfizer has completed a Phase 1 trial titled “A Phase 1, Randomized, ...

Pfizer’s PFE top line has been declining in 2023 due to a steep drop in revenues from its COVID-19 products, the Comirnaty vaccine and Paxlovid oral pill, on lower demand due to the end of the ...

Analysts predict Pfizer's Q2 2024 revenue to be around $13 billion . The EPS estimate for Q2 2024 is $0.22, reflecting challenges from decreased COVID-19 product demand. Investors are closely watching ...

Pfizer partners with Cipla, granting exclusive rights to market key medicines, including Corex Dx and Corex LS, in India.

Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. Keep your expectations in check.

(Reuters) -Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, boosted by cost cutting efforts and stronger-than-expected sales of ...

In another bid to widen access to its medical products, Pfizer plans to provide roughly 500 medicines and vaccines — many of which are no longer protected by patents — at not-for-profit prices to 45 ...

Pfizer on Tuesday reported its first quarterly loss since 2019 as demand for its COVID products dwindled. Sales of the company's coronavirus vaccine Comirnaty dropped 70% during the third quarter ...

The drop reflects investors reactions to Pfizer’s new 2026 revenue forecasts, which is set to be between the range of $59.5 ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Increasing worldwide access to affordable prescription drugs ...